BLOG

Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD

Oxurion announced that it entered into a strategic research collaboration with Beta Therapeutics (Canberra, Australia) to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration.